Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report
نویسندگان
1 The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, Jiangsu, China.
2 Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
3 Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
4 Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
5 Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
6 Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
7 The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, Jiangsu, China.
doi
10.22034/iji.2023.99254.2629چکیده
Hemophagocytic lymphohistiocytosis (HLH) is a fatal clinical syndrome. The most common cause of secondary HLH is Epstein-Barr virus (EBV) infection. EBV-HLH is a common clinical disease with high mortality, easy relapse, and poor prognosis. Therefore, treating EBV-HLH with T and B lymphocyte involvement is challenging, and selecting an appropriate treatment regimen is critical. Moreover, research on how to evaluate the recurrence index after remission is scarce. In this study, we reported a case of EBV-HLH successfully treated with programmed cell death protein-1 (PD-1) inhibitor in combination with rituximab. The regimen had a good curative effect, and we successfully detected the trend of early recurrence. Our findings indicated that PD-1 inhibitor in combination with rituximab may help to treat EBV-HLH and maintain EBV-infected T and B whole-line lymphocytes.
